Abstract
Psoriasis is a chronic inflammatory proliferative skin disease induced by aberrant cellular immunity under the interactive effect between polygenic and environmental factors. The exact pathogenesis of psoriasis remains unclear, and interleukin-17 (IL-17)is currently considered to play a critical role in it by stimulating the proliferation and aberrant activation of keratinocytes. Three newly developed biological agents targeting the interleukin-17 pathway have been used to treat psoriasis in clinical trials or practice, including secukinumab and ixekizumab that directly antagonize IL-17A, as well as brodalumab that inhibits downstream signal molecules of the IL-17 signaling pathway by antagonizing IL-17RA. They have proved to be effective and safe in the treatment of psoriasis vulgaris and psoriatic arthritis in clinical trials, and provided new choices for the treatment of psoriasis. However, there is still a need for long-term evaluation of their safety. Key words: Psoriasis; Interleukin-17; Biological agents; Therapeutic uses; Safety
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
